Abstract
Alzheimer’s disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.
Keywords: Aβ, Alzheimer’s disease, cholinesterase inhibitors, hybrids, memantine, neurodegeneration.
Current Pharmaceutical Analysis
Title:Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Volume: 12 Issue: 2
Author(s): Vladan Bajic, Emina Sudar Milovanovic, Biljana Spremo-Potparevic, Lada Zivkovic, Zorka Milicevic, Julijana Stanimirovic, Nikola Bogdanovic and Esma R. Isenovic
Affiliation:
Keywords: Aβ, Alzheimer’s disease, cholinesterase inhibitors, hybrids, memantine, neurodegeneration.
Abstract: Alzheimer’s disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.
Export Options
About this article
Cite this article as:
Bajic Vladan, Milovanovic Sudar Emina, Spremo-Potparevic Biljana, Zivkovic Lada, Milicevic Zorka, Stanimirovic Julijana, Bogdanovic Nikola and Isenovic R. Esma, Treatment of Alzheimer's Disease: Classical Therapeutic Approach, Current Pharmaceutical Analysis 2016; 12 (2) . https://dx.doi.org/10.2174/1573412911666150611184740
DOI https://dx.doi.org/10.2174/1573412911666150611184740 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid Modulation of Intravascular and Cellular Sodium Handling:Mechanistic Insights and Potential Clinical Implications
Current Vascular Pharmacology The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Hepatocyte Growth Factor and Insulin-like Growth Factor-1 based Cellular Therapies for Oxidative Stress Injury
Current Stem Cell Research & Therapy The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis
Current Alzheimer Research Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Antiglucocorticoids, Neurogenesis and Depression
Mini-Reviews in Medicinal Chemistry The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease
Current Alzheimer Research MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches
Current Pharmaceutical Biotechnology Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Complex Polyamines: Unique Prion Disaggregating Compounds
CNS & Neurological Disorders - Drug Targets Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design Amyloid-β Inhibits PDGFβ Receptor Activation and Prevents PDGF-BBInduced Neuroprotection
Current Alzheimer Research Targeting CCK Receptors in Human Cancers
Current Topics in Medicinal Chemistry Interleukin-18: Biology and Role in the Immunotherapy of Cancer
Current Medicinal Chemistry (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry